| Home | E-Submission | Sitemap | Contact Us |  
Clin Exp Emerg Med > Volume 7(4); 2020 > Article
Özturan, Köse, Özkan, and Köse: Myopericarditis caused by severe acute respiratory syndrome coronavirus 2


A 25-year-old man presented to the emergency department with acute-onset chest pain and shortness of breath. A physical examination revealed coarse crackles in the both lower lungs. Consolidation and ground-glass opacities suggesting viral infection were detected in the right lower lobe on chest computed tomography. Laboratory findings revealed elevated troponin, leukocytosis, and lymphopenia. Electrocardiography revealed ST segment elevation with PR depression in leads I, aVL, V5, and V6, and ST depression and PR elevation in aVR. Echocardiography revealed diffuse cardiac hypokinesia and a decreased left ventricular ejection fraction. Suspecting coronavirus disease 2019 (COVID-19)–related myopericarditis, the patient was hospitalized. After one week of empirical antibiotics, antivirals, and supportive therapy, his condition improved. Antibody testing for COVID-19 was positive on hospitalization day 8. The presentation of myopericarditis can be vague and mislead physicians during the COVID-19 pandemic. Myopericarditis should be included as a differential diagnosis for patients with suspected COVID-19.


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) was first reported in China in December 2019. Subsequently, it was declared as a pandemic by the World Health Organization in March 2020, and the global burden of COVID-19 was reported as 37,888,384 cases and 1,081,868 deaths as of October 14, 2020 [1].
While most COVID-19-related clinical conditions are associated with the respiratory system, cardiovascular involvement is also common and related to high mortality rates among hospitalized patients [2]. Previous studies have reported that SARS-CoV-2 can cause myocardial injury and elevated troponin levels [3]. However, it has been suggested that the myocardial injury is related to the systemic effects of COVID-19, rather than direct damage to the cardiac tissue [3]. A limited number of case reports have demonstrated myopericarditis in patients with COVID-19.
We report a case of COVID-19-associated myopericarditis and review the current literature to increase emergency physicians’ awareness of COVID-19-associated myopericarditis as they care for patients with COVID-19.


A 25-year-old man presented to the emergency department (ED) with acute onset chest pain and shortness of breath (SOB). The patient’s medical history was unremarkable; however, the patient had a 4-day history of progressive fatigue and fever. In the ED, the patient’s blood pressure was 130/80 mmHg, heart rate was 140 beats per minute, oxygen saturation was 98% in room air, and temperature was 37.1°C. A physical examination revealed tachycardia and coarse crackles in the both lower lung zones. An electrocardiogram (ECG) showed sinus tachycardia with ST segment elevation and PR depression in leads I, aVL, V5, and V6 and ST depression and PR elevation in aVR (Fig. 1A). The initial laboratory work-up revealed leukocytosis, lymphopenia, and elevated troponin (21.471 ng/mL; normal range, 0–60 ng/mL). An echocardiogram demonstrated diffuse left ventricular hypokinesia with an ejection fraction of 35% and a pulmonary artery pressure of 30 mmHg. Consolidation and ground-glass opacities suggesting viral infection were detected in the right lower lobe on chest computed tomography (Fig. 1B). The patient was transferred to the cardiac care unit with the suspicion of COVID-19-related myopericarditis. Although the initial polymerase chain reaction testing for SARS-CoV-2 was negative, considering the high clinical suspicion of COVID-19, the patient was kept under isolation and empirical antibiotics, antivirals, and supportive therapy were initiated, including ampicillin-sulbactam (1.5 g four times a day), clarithromycin (500 mg twice a day), oseltamivir (75 mg twice a day), acetylsalicylic acid (81 mg once a day), and metoprolol (50 mg twice a day). An emergency coronary angiography was not performed as the patient’s clinical condition was attributed to the viral infection. The patient’s sputum, blood, and urine cultures were negative. The patient was treated in the cardiac care unit for 8 days, during which his laboratory and radiological findings normalized (Table 1). An echocardiogram showed a left ventricular ejection fraction of 55% prior to discharge. Antibody testing for COVID-19 was positive on the 8th day of hospitalization. The patient provided written informed consent for this report.


Myopericarditis is a challenging diagnosis encountered in the ED. Although it should be suspected in any patients with chest pain, increased troponin levels, and dynamic ECG changes, these findings are non-specific and can also be seen in patients with systemic infections, including those with COVID-19 [4]. The cardiovascular complications of COVID-19 have been previously reported [2]; however, reports of patients presenting to the ED with the suspicion of COVID-19-related myopericarditis are scarce.
Most patients with COVID-19 present to the ED with fever, cough, and SOB [5]. The presentation of patients with COVID-19–associated myopericarditis can be non-specific. To date, only a few cases of myocarditis or myopericarditis associated with COVID-19 have been reported in the literature [6-15]. The most common symptoms at presentation included SOB (6/10 cases) [6,9,11,13-15], chest pain (6/10 cases) [6,10-12,14,15], and fever (5/10 cases) [6,8-10,13]. However, diarrhea (4/10 cases) [8,9,13,15], fatigue (2/10 cases) [7,12], and cough (2/10 cases) [8,9] have also been reported (Supplementary Table 1). Therefore, even without chest pain or other common symptoms, COVID-19 can present with myopericarditis.
Cardiac biomarkers such as troponin or N-terminal pro-B-type natriuretic peptide (NT-proBNP) were elevated in patients with myopericarditis [2]. Previous studies reported that both troponin and NT-proBNP were simultaneously elevated in patients with COVID-19 and myopericarditis [6-8,10,11,13,15]. Therefore, these cardiac biomarkers should be tested in patients suspected of having COVID-19–associated myopericarditis. In this patient, NT-proBNP was not tested due to echocardiographic findings supporting the diagnosis.
Utilizing echocardiography as an initial diagnostic workup in the ED may facilitate the care of patients with myopericarditis [2]. Although cardiac magnetic resonance imaging is widely used to diagnose myopericarditis, it is not a feasible diagnostic tool in the ED. The most common echocardiographic findings are myocardial dyskinesia with a decreased left ventricular ejection fraction [6-8,10,11,13,15]. In this report, the patient had an initial left ventricular ejection fraction of 35% and diffuse myocardial hypokinesia, which were improved at the time of discharge.
In conclusion, myopericarditis is an insidious condition that can accompany COVID-19. Emergency physicians should consider myopericarditis as an important differential diagnosis for patients with COVID-19.


No potential conflict of interest relevant to this article was reported.

Supplementary Materials

Supplementary Table is available from: https://doi.org/10.15441/ceem.20.109.
Supplementary Table 1.
The literature on the presented case


1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Oct 14]. Available from: https://covid19.who.int.

2. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020; 38:1504-7.
crossref pmid pmc
3. Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol 2020; 311:116-21.
crossref pmid pmc
4. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail 2020; 26:470-5.
crossref pmid pmc
5. Duanmu Y, Brown IP, Gibb WR, et al. Characteristics of emergency department patients with COVID-19 at a single site in Northern California: clinical observations and public health implications. Acad Emerg Med 2020; 27:505-9.
6. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 2020; 48:773-7.
crossref pmid
7. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:819-24.
crossref pmid
8. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J 2020; 41:1859.
crossref pmid
9. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet 2020; 395:1516.
crossref pmid pmc
10. Irabien-Ortiz A, Carreras-Mora J, Sionis A, Pamies J, Montiel J, Tauron M. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol 2020; 73:503-4.
crossref pmc
11. Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 2020; 41:1861-2.
crossref pmid
12. Paul JF, Charles P, Richaud C, Caussin C, Diakov C. Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovasc Imaging 2020; 21:776.
13. Coyle J, Igbinomwanhia E, Sanchez-Nadales A, Danciu S, Chu C, Shah N. A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. JACC Case Rep 2020; 2:1331-6.
14. Cizgici AY, Zencirkiran Agus H, Yildiz M. COVID-19 myopericarditis: It should be kept in mind in today’s conditions. Am J Emerg Med 2020; 38:1547.

15. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020; 2020; Mar; 16; https://doi.org/10.1093/eurheartj/ehaa190.

Fig. 1.
Electrocardiogram and computerized tomography findings of the patients. (A) Electrocardiogram findings of the patients. (B) Consolidation and ground glass opacities on the computed tomography image.
Table 1.
Progression of laboratory findings
Day 1 Day 2 Day 3 Day 4
TnI (ng/mL) 6.499 3.197 1.137 0.161
 ref: 0.012–0.02 ng/mL
CK-MB (ng/mL) 37.1 8.4 1.8 3
 ref: 0.6–6.3 ng/mL
WBC (× 103/μL) 11.58 12.76 NT NT
 ref: 4.5–11 × 103/μL
CRP (mg/L) 47.10 50.64 67.11 14.85
 ref: < 5 mg/L
Lymphocyte (× 103/μL) 1.00 NT NT NT
 ref 1.5–4 × 103/μL

TnI, troponin I; CK-MB, creatine kinase-MB; WBC, white blood cells; CRP, C-reactive protein; NT, not tested.

Editorial Office
The Korean Society of Emergency Medicine
101-3104, Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 04510, Korea
TEL: +82-70-4206-7190   FAX: +82-2-3676-1339   E-mail: office@ceemjournal.org
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © by The Korean Society of Emergency Medicine.                 Developed in M2PI